Ocuphire is developing a ‘pipeline within a product’ for its lead ophthalmic drug candidate Nyxol. The most advanced front of the eyes clinical programs target night vision disturbances and glaucoma. Nyxol has been studied in 5 completed randomized placebo-controlled Phase 1 and 2 trials with over 100 subjects treated. Nyxol is being advanced through the 505(b)(2) pathway in the United States with a broad global patent estate fully owned by Ocuphire, covering the novel eye drop formulation and methods of use at least through 2034. Ocuphire is interested in adding novel ophthalmic early to mid-stage clinical drug candidates to the portfolio, please contact us with such business development opportunities.